Avicanna Stock Fundamentals
| AVCNF Stock | USD 0.25 0.04 19.05% |
Avicanna fundamentals help investors to digest information that contributes to Avicanna's financial success or failures. It also enables traders to predict the movement of Avicanna OTC Stock. The fundamental analysis module provides a way to measure Avicanna's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Avicanna otc stock.
Avicanna |
Avicanna OTC Stock Shares Outstanding Analysis
Avicanna's Outstanding Shares are shares of common stock of a public company that were purchased by investors after they were authorized and issued by the company to the public. Outstanding Shares are typically reported on fully diluted basis, including exotic instruments such as options, or convertibles bonds.
Current Avicanna Shares Outstanding | 74.52 M |
Most of Avicanna's fundamental indicators, such as Shares Outstanding, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Avicanna is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Outstanding shares that are stated on company Balance Sheet are used when calculating many important valuation and performance indicators including Return on Equity, Market Cap, EPS and many others.
| Competition |
Based on the latest financial disclosure, Avicanna has 74.52 M of shares currently outstending. This is 58.72% lower than that of the Healthcare sector and significantly higher than that of the Drug Manufacturers—Specialty & Generic industry. The shares outstanding for all United States stocks is 86.97% higher than that of the company.
Avicanna Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Avicanna's current stock value. Our valuation model uses many indicators to compare Avicanna value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Avicanna competition to find correlations between indicators driving Avicanna's intrinsic value. More Info.Avicanna is rated third in return on equity category among its peers. It is rated fifth in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Avicanna's earnings, one of the primary drivers of an investment's value.Avicanna Shares Outstanding Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Avicanna's direct or indirect competition against its Shares Outstanding to detect undervalued stocks with similar characteristics or determine the otc stocks which would be a good addition to a portfolio. Peer analysis of Avicanna could also be used in its relative valuation, which is a method of valuing Avicanna by comparing valuation metrics of similar companies.Avicanna is currently under evaluation in shares outstanding category among its peers.
Avicanna Fundamentals
| Return On Equity | -1.69 | |||
| Return On Asset | -0.22 | |||
| Operating Margin | (2.11) % | |||
| Current Valuation | 20.15 M | |||
| Shares Outstanding | 74.52 M | |||
| Shares Owned By Insiders | 22.52 % | |||
| Price To Book | 9.32 X | |||
| Price To Sales | 4.51 X | |||
| Revenue | 3.27 M | |||
| Gross Profit | 2.83 M | |||
| EBITDA | (15.13 M) | |||
| Net Income | (16.77 M) | |||
| Cash And Equivalents | 685.94 K | |||
| Cash Per Share | 0.01 X | |||
| Total Debt | 415.83 K | |||
| Debt To Equity | 0.31 % | |||
| Current Ratio | 0.90 X | |||
| Book Value Per Share | 0.04 X | |||
| Cash Flow From Operations | (11.66 M) | |||
| Earnings Per Share | (0.26) X | |||
| Number Of Employees | 124 | |||
| Beta | 1.94 | |||
| Market Capitalization | 22.99 M | |||
| Total Asset | 22.3 M | |||
| Z Score | 33.0 | |||
| Net Asset | 22.3 M |
About Avicanna Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Avicanna's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Avicanna using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Avicanna based on its fundamental data. In general, a quantitative approach, as applied to this otc stock, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.Avicanna Inc., a commercial-stage biopharmaceutical company, engages in the research and development of evidence-based products for consumer medical and pharmaceutical segments worldwide. Avicanna Inc. was incorporated in 2016 and is headquartered in Toronto, Canada. Avicanna operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on OTC Exchange. It employs 124 people.
Currently Active Assets on Macroaxis
Other Information on Investing in Avicanna OTC Stock
Avicanna financial ratios help investors to determine whether Avicanna OTC Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Avicanna with respect to the benefits of owning Avicanna security.